Trial Profile
Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®) for Blood Pressure Reduction in Patients With Primary Intracerebral Hemorrhage: A Randomized Controlled Trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Clevidipine (Primary) ; Urapidil
- Indications Hypertension
- Focus Therapeutic Use
- 02 Nov 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 25 Mar 2019 Planned End Date changed from 30 Sep 2019 to 30 Sep 2021.
- 25 Mar 2019 Planned primary completion date changed from 14 Jun 2019 to 14 Jun 2021.